LivsMed posted operating losses in both 2024 and 2025, with revenue growing and losses narrowing. Revenue rose 88.8% from KRW 27.1 billion in 2024 to KRW 51.2 billion in 2025, while the operating loss narrowed from KRW 26.5 billion to KRW 22.6 billion. The operating margin improved from -97.7% to -44.2%.
The net loss attributable to controlling shareholders narrowed from KRW 25.6 billion in 2024 to KRW 22.9 billion in 2025, and the net loss including non-controlling interests narrowed over the same period from KRW 25.6 billion to KRW 22.9 billion.
Operating cash flow worsened from -KRW 27.7 billion in 2024 to -KRW 34.7 billion in 2025. The company attributed the 2025 losses to investment costs for the STARK surgical robot, new product certifications and overseas market development for the ArtiSeal vascular closure device.
The debt ratio fell from 34.5% in 2024 to 11.6% in 2025. In 2026, revenue was KRW 10.3 billion in the first quarter with an operating loss of KRW 8.37 billion, and in the second quarter revenue rose to KRW 12.5 billion (up 21.9% from the prior quarter) while the operating loss widened to KRW 12.2 billion.
Third-quarter revenue was KRW 8.92 billion, down 28.7% from the prior quarter, and the operating loss narrowed to KRW 10.4 billion. The net loss attributable to controlling shareholders in the third quarter was KRW 15.5 billion, larger than the operating loss.
Based on the first-half 2026 figures reported by the press, the gross margin fell from 61.3% to 43.4%, and general and administrative R&D expenses rose 51.5%.
The company attributed the third-quarter revenue decline to the sell-through of the previous-generation product ahead of the ArtiSential PRO launch and to inventory adjustments in the distribution channel.